evrazkarЕвразийский Кардиологический ЖурналEurasian heart journal2225-16852305-0748Евразийская ассоциация кардиологов10.38109/2225-1685-2013-1-31-39evrazkar-5537Research ArticleОРИГИНАЛЬНЫЕ СТАТЬИORIGINAL PAPERSРАСПРОСТРАНЕННОСТЬ КОМПОНЕНТОВ МЕТАБОЛИЧЕСКОГО СИНДРОМА У БОЛЬНЫХ ИШЕМИЧЕСКОЙ БОЛЕЗНЬЮ СЕРДЦА В ПОПУЛЯЦИИ Г. ЕРЕВАНА (АРМЕНИЯ)PPREVALENCE OF COMPONENTS OF THE METABOLIC SYNDROME IN PATIENTS WITH ISCHEMIC HEART DISEASE IN YEREVAN POPULATION., ARMENIAМогадамЭзат ФазелиMogadamE. F.ztfazeli@yahoo.comТадевосянАрташес ЭдуардовичTadevosyanA. E.artashes.tadevosyan@meduni.amПодосянГеворг АршалуйсовичPodosyanG. A.gpodosyan@yahoo.comЗелвеянПарунак АрутюновичZelveianP. H.zelveian@hotmail.comЕреванский государственный медицинский университет им. М. Гераци; Университет медицинских наукРоссияUniversities of Medical SciencesRussian FederationЕреванский государственный медицинский университет им. М. ГерациРоссияYerevan State Medical University after M. HeratsiRussian FederationЦентр превентивной кардиологииРоссияCenter of Preventive CardiologyRussian FederationЦентр превентивной кардиологии; Национальный институт здравоохранения МЗ РАРоссияCenter of Preventive Cardiology; National Institute of Health MOH RARussian Federation201330032013013139Copyright © Могадам Э.Ф., Тадевосян А.Э., Подосян Г.А., Зелвеян П.А., 20132013Могадам Э.Ф., Тадевосян А.Э., Подосян Г.А., Зелвеян П.А.Mogadam E.F., Tadevosyan A.E., Podosyan G.A., Zelveian P.H.Данная работа распространяется под лицензией Creative Commons Attribution 4.0.This work is licensed under a Creative Commons Attribution 4.0 License.https://www.heartj.asia/jour/article/view/5537

Целью данного исследования явилось изучение взаимосвязи метаболического синдрома (МС) и его составляющих с ишемической болезнью сердца (ИБС) среди взрослого населения г. Еревана (Армения). Методы. За период 2010-2011 гг. в клиниках Ереванского государственного медицинского университета и в Центре превентивной кардиологии были рандомизированы 320 больных со стабильными формами ИБС (средний возраст 57,2±10,9 лет) и 320 - без ИБС (средний возраст 55,5±11,7 лет). Все больные обследовались согласно современным рекомендациям клиникоинструментальных и лабораторных исследований. Диагноз МС определялся по критериям AHA/NHLBI, 2005. Результаты исследования статистически обработаны методами параметрической и непараметрической статистики, достоверной считалась вероятность ошибки p<0,05. Результаты. Полученные результаты показали, что содержание в плазме крови триглицеридов (p<0,05), систолическое АД (p<0,05) и окружность талии (p<0,001) достоверно выше у больных ИБС, чем у лиц контрольной группы. Разница между показателями липопротеидов высокой плотности и индексами массы тела обеих групп не наблюдалась. Наиболее частым фактором риска как в исследуемой, так и в контрольной группах было высокое АД (78% и 64% соответственно; p<0,001). По критериям AHA/NHLBI, распространенность МС была 79,7% в исследуемой и 69,4% в контрольной группе, тогда как сахарный диабет превалировал в контрольной группе (27,1% против 15,5%). Между исследуемой и контрольной группами достоверная разница распространенности МС выявлялась только при комбинации всех компонентов МС. Существенная разница в этом аспекте между классификациями МС согласно AHA/NHLBI и Международной федерации диабетологов (МФД) не была выявлена. Заключение. Распространенность метаболического синдрома достоверно выше у больных с ИБС, что проявляется при учете всех его компонентов. Критерии детерминации метаболического синдрома AHA/NHLBI и МФД в практическом применении считаются эквивалентными.

The research objective was aimed at the study of association of metabolic syndrome (MetS) and its components with coronary heart disease (CHD) among the population of Yerevan city (Armenia). Methods. During 2010-2011 in clinics of the Yerevan State Medical University and in the Center of preventive cardiology 320 patients with stable forms CHD (mean age 57.2±10.9 years) and 320 subjects without CHD (mean age 55.5± 11.7 years) were randomly selected. All patients have been surveyed according to current recommendations of clinical, instrumental and laboratory guidances. Diagnosis of MetS was defined by criteria AHA/NHLBI (2005). Biochemical analysis of blood made in hospital laboratories and anthropometrical indicators measured on standard procedures. Other data were obtained by use of the standard questionnaires. Study results were exposed to statistical processing by the parametric and nonparametric statistics methods, the zero hypothesis was rejected at p <0.05. Results. Obtained results indicated that among patients with CHD the blood plasma concentration of triglycerides (p<0.05) and systolic blood pressure (BP) (p<0.05) were considerably higher and waist circumference (p<0.001) as well was bigger in comparison with control group. The differences between indicators of high density lipoproteins and body mass index were not observed in both groups. High BP was the most frequent risk factor both in investigated and control groups (78% and 64% accordingly, p<0.001). By AHA/NHLBI criteria, prevalence of MetS amounted to 79.7% in investigated and 69.4% in control group, whereas the diabetes mellitus was more often observed in control group (27.1% against 15.5%). The authentic differences in prevalence of МetS between investigated and control groups were revealed only in combination of all components of МetS. In this respect significant difference between classifications of МetS according to AHA/NHLBI and IDF does not come to light. Conclusion. The prevalence of MetS was higher among patients with a CHD that was shown in full clusters. From practical point of view AHA/NHLBI and IDF criteria of a metabolic syndrome are equivalent.

метаболический синдромишемическая болезнь сердцараспространенностьЕреванАрменияmetabolic syndromecoronary heart diseaseprevalenceYerevanArmeniaReferencesHoang K.C., Ghandehari H., Lopez V.A., et al. Global Coronary Heart disease risk assessment of individuals with the metabolic syndrome in the U.S. Diabetes Care 2008; 31(7): 1405-9.Hoang K.C., Ghandehari H., Lopez V.A., et al. Global Coronary Heart disease risk assessment of individuals with the metabolic syndrome in the U.S. Diabetes Care 2008; 31(7): 1405-9.ExecutiveSummary of the third report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). JAMA 2001; 285(19): 2486-97.ExecutiveSummary of the third report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). JAMA 2001; 285(19): 2486-97.Grundy S.M., Cleeman J.I., Daniels S.R., et al. Diagnosis an Management of the Metabolic Syndrome: An American Heart Association/National Heart, Lung, and Blood Institute Scientific Statement: Executive Summary. Circulation 2005; 112: e285-e290.Grundy S.M., Cleeman J.I., Daniels S.R., et al. Diagnosis an Management of the Metabolic Syndrome: An American Heart Association/National Heart, Lung, and Blood Institute Scientific Statement: Executive Summary. Circulation 2005; 112: e285-e290.Zimmet P., Alberti K.G., Rlosc M.S. A New International Diabetes Federation Worldwide Definition of the Metabolic Syndrome: the Rationale and the Results. Rev EspCardiol 2005; 58(12): 1371-6.Zimmet P., Alberti K.G., Rlosc M.S. A New International Diabetes Federation Worldwide Definition of the Metabolic Syndrome: the Rationale and the Results. Rev EspCardiol 2005; 58(12): 1371-6.Hadaegh F., Zabetian A., Tohidi M., et al. Prevalence of Metabolic Syndrome by the Adult Treatment Panel III, International Diabetes Federation, and World Health Organization Definitions and their Association with Coronary Heart Disease in an Elderly Iranian Population. Ann Acad Med (Singapore) 2009; 38: 142.Hadaegh F., Zabetian A., Tohidi M., et al. Prevalence of Metabolic Syndrome by the Adult Treatment Panel III, International Diabetes Federation, and World Health Organization Definitions and their Association with Coronary Heart Disease in an Elderly Iranian Population. Ann Acad Med (Singapore) 2009; 38: 142.McNeill A.M., Rosamond W.D., Girman C.J., et al. The metabolic syndrome and 11-year risk of incident cardiovascular disease in the atherosclerosis risk in communities study. Diabetes Care 2005; 28: 385-90.McNeill A.M., Rosamond W.D., Girman C.J., et al. The metabolic syndrome and 11-year risk of incident cardiovascular disease in the atherosclerosis risk in communities study. Diabetes Care 2005; 28: 385-90.Daly C.A., Hildebrandt P., Bertrand M., et al. Adverse prognosis associated with the metabolic syndrome in established coronary artery disease: data from the EUROPA trial. Heart 2007; 93: 1406-11.Daly C.A., Hildebrandt P., Bertrand M., et al. Adverse prognosis associated with the metabolic syndrome in established coronary artery disease: data from the EUROPA trial. Heart 2007; 93: 1406-11.Iribarren C., Go A.S., Husson G., et al. Metabolic Syndrome and Early-Onset Coronary Artery Disease: is the Whole Greater Than It's Parts? J Am CollCardiol 2006; 48: 1800-7.Iribarren C., Go A.S., Husson G., et al. Metabolic Syndrome and Early-Onset Coronary Artery Disease: is the Whole Greater Than It's Parts? J Am CollCardiol 2006; 48: 1800-7.Mamedov M.N., Poddubskaya E.A., Didigov R.T. Possibility of self-control the metabolic syndrome in the home. Kardiologia 2011; 19(5): 329-32. Russian (Мамедов М.Н., Поддубская Е.А., Дидигов Р.Т. Возможности самоконтроля проявлений метаболического синдрома в домашных условиях. Кардиология 2011,19(5): 329-32.).Mamedov M.N., Poddubskaya E.A., Didigov R.T. Possibility of self-control the metabolic syndrome in the home. Kardiologia 2011; 19(5): 329-32. Russian (Мамедов М.Н., Поддубская Е.А., Дидигов Р.Т. Возможности самоконтроля проявлений метаболического синдрома в домашных условиях. Кардиология 2011,19(5): 329-32.).Zelveian P.A., Podosyan G.A., Barsamyan S.G., et al. Distribution, awareness and control of blood pressure in Yerevan, Armenia. Journal of Hypertension 2008; 26: Suppl.1: S.100.Zelveian P.A., Podosyan G.A., Barsamyan S.G., et al. Distribution, awareness and control of blood pressure in Yerevan, Armenia. Journal of Hypertension 2008; 26: Suppl.1: S.100.Podosyan G.A. Prevalence of abdominal obesity among adult population of Yerevan City and its relationship with arterial hypertension. Scientific papers of VII Congress of Armenian Cardiologists. 2009: 65.[Armenian]Podosyan G.A. Prevalence of abdominal obesity among adult population of Yerevan City and its relationship with arterial hypertension. Scientific papers of VII Congress of Armenian Cardiologists. 2009: 65.[Armenian]Brown T.M., Vaidya D., Rogers W.J., et al. Prevalence of the Metabolic Syndrome in Women with Coronary Artery Disease Differ by the ATP III and IDF Criteria? Journal of Women's Health 2008; 17(5): 841-7.Brown T.M., Vaidya D., Rogers W.J., et al. Prevalence of the Metabolic Syndrome in Women with Coronary Artery Disease Differ by the ATP III and IDF Criteria? Journal of Women's Health 2008; 17(5): 841-7.Jeremy R.W. Metabolic syndrome - is the whole really greater than the sum of the parts? Heart Lung and Circulation 2011; 20: 211-3.Jeremy R.W. Metabolic syndrome - is the whole really greater than the sum of the parts? Heart Lung and Circulation 2011; 20: 211-3.Simons L.A., Simons J., Friedlander Y., et al. Is prediction of cardiovascular disease and all-cause mortality genuinely driven by the Metabolic Syndrome, and independently from its component variables? The Dubbo Study. Heart Lung and Circulation 2011; 20: 214-9.Simons L.A., Simons J., Friedlander Y., et al. Is prediction of cardiovascular disease and all-cause mortality genuinely driven by the Metabolic Syndrome, and independently from its component variables? The Dubbo Study. Heart Lung and Circulation 2011; 20: 214-9.Malik S., Wong N.D., Franklin S.S., et al. Impact of the Metabolic Syndrome on mortality from coronary heart disease, cardiovascular disease, and all causes in United States adults. Circulation 2004; 110: 1245-50.Malik S., Wong N.D., Franklin S.S., et al. Impact of the Metabolic Syndrome on mortality from coronary heart disease, cardiovascular disease, and all causes in United States adults. Circulation 2004; 110: 1245-50.

The authors declare that there are no conflicts of interest present.